Telara Pharma SL
Latest round
- Seed
Last raised
- May 2021
Total raised
- $0.1M
Investors
- 1
About Telara Pharma SL
Telara Pharma SL specializes in repurposing cilastatin to create therapies for severe inflammatory disorders, particularly Acute Kidney Injury (AKI).Telara Pharma specializes in repurposing cilastatin, a drug initially used to address various kidney functions, into innovative therapies aimed at treating severe inflammatory disorders, particularly Acute Kidney Injury (AKI). The core product, cilastatin, functions as a competitive blocker of renal dehydropeptidase I (DHP-I), protecting renal tubular cells from damage caused by nephrotoxic agents, such as cisplatin, cyclosporine, and gentamicin, as well as conditions like sepsis. The company’s research has established cilastatin as a promising therapeutic alternative to currently unapproved drug therapies for AKI, which affects millions globally.The revenue model of Telara Pharma is centered around partnerships and collaborations with healthcare entities, clinical trial sponsors, and potentially pharmaceutical companies looking to license cilastatin for further development. The company’s transactions typically occur through licensing agreements for their flagship product, cilastatin, which is in advanced clinical trial phases aimed at mitigating the impact of AKI caused by both toxic agents and sepsis. These agreements may involve milestone payments, royalties, or profit-sharing arrangements contingent upon successful trial outcomes and subsequent market entry. The company also anticipates revenue from future proprietary programs targeting neuroinflammatory disorders, further diversifying its income streams as they advance their clinical pipeline.Telara Pharma plans to continue developing cilastatin as a therapy for Acute Kidney Injury and is also exploring new proprietary programs aimed at treating neuroinflammatory disorders. The company is focused on expanding into North American and European markets where there is a high demand for effective AKI treatments.
Who invested in Telara Pharma SL
1 investor across 1 round
See all investors in Telara Pharma SL
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
May 10, 2021
Amount
$0.1M
Investors
Questions about Telara Pharma SL
Who invested in Telara Pharma SL?
Telara Pharma SL has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Telara Pharma SL raised?
Telara Pharma SL has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Telara Pharma SL last raise money?
Telara Pharma SL's most recent round on record is a Seed, in May 2021.
What does Telara Pharma SL do?
Telara Pharma SL specializes in repurposing cilastatin to create therapies for severe inflammatory disorders, particularly Acute Kidney Injury (AKI).
Where is Telara Pharma SL headquartered?
Telara Pharma SL is headquartered in Madrid, Spain.
Which VCs invest in companies like Telara Pharma SL?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Telara Pharma SL's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Telara Pharma SL? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.